Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Children's Hospital Los Angeles.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT00730314
First received: August 6, 2008
Last updated: June 22, 2011
Last verified: June 2011
  Purpose

This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. Genetic diseases of blood cell include: Red blood cell defects e.g. hemoglobinopathies (sickle cell disease and thalassemia), Blackfan-Diamond anemia and congenital or chronic hemolytic anemias; White blood cells defects/immune deficiencies e.g. chronic granulomatous disease, Wiskott-Aldrich syndrome,Osteopetrosis, Kostmann's syndrome (congenital neutropenia), Hereditary Lymphohistiocytosis (HLH); Platelets defects e.g.Congenital amegakaryocytic thrombocytopenia; Metabolic/storage disorders e.g. leukodystrophies,mucopolysaccharidoses as Hurler disease;Stem cell defects e.g.reticular agenesis, among many other rare similar conditions.

The study treatment plan uses a new transplant treatment regimen that aims to try to decrease the acute toxicities and complications associated with the standard treatment plans and to improve outcome

The blood stem cells will be derived from either unrelated donor or unrelated umbilical cord blood.


Condition Intervention Phase
Sickle Cell Disease
Thalassemia
Anemia
Granuloma
Wiskott-Aldrich Syndrome
Chediak Higashi Syndrome
Osteopetrosis
Neutropenia
Thrombocytopenia
Hurler Disease
Niemann-Pick Disease
Fucosidosis
Procedure: Hematopoietic stem cell transplantation
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Children's Hospital Los Angeles:

Primary Outcome Measures:
  • toxicities [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • adverse events [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • engraftment [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • immune reconstitution [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • overall and event free survival survival [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 25
Study Start Date: August 2008
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Unrelated donor
Procedure: Hematopoietic stem cell transplantation
hematopoietic stem cell transplantation conditioning regimen depending on graft source
Experimental: 2
Cord Blood
Procedure: Hematopoietic stem cell transplantation
hematopoietic stem cell transplantation conditioning regimen depending on graft source

Detailed Description:

This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).

We hypothesize that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of fludarabine to a conditioning regimen with myeloablative doses of Busulfan and reduced dosages of Cytoxan prior to HSCT will overcome the engraftment barrier posed by an intact immune system, which is seen in patients with a genetic disease.

  Eligibility

Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Lethal or sublethal genetic disease of blood cells, who lack a fully histocompatible sibling or other family donor
  • Genetic diseases that would be candidates for this protocol includes those that have been shown to benefit from allogeneic HSCT: Red blood cell defects, Leukocyte defects/ Primary immune deficiencies, Platelets defects, Metabolic/storage disorders and Stem cell defects.
  • Renal: creatinine clearance or glomerular filtration rate (GFR) ≥50 ml/min/1.73m2 and not requiring dialysis.
  • Pulmonary: FEV1, FVC and DLCO (corrected for hemoglobin) ≥ 50% predicted. if unable to perform pulmonary function tests, then O2 saturation ≥ 92% in room air.
  • Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening fraction ≥ 26%
  • Hepatic: Bilirubin ≤3x upper limit of normal (ULN) and ALT and AST ≤ 5x for age (with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome).
  • Patients will be 0-21 years of age.
  • Disease specific inclusion criteria (as applicable per protocol).

Exclusion Criteria:

  • Recipients should not have any of the general exclusion criteria, and disease specific exclusion criteria when applicable.
  • Patient with histocompatible sibling
  • End-organ failure that precludes the ability to tolerate the transplant procedure, including the conditioning regimen.
  • Creatinine clearance or GFR < 50 ml/min/1.73m2 or renal failure requiring dialysis.
  • Congenital heart disease resulting in congestive heart failure.
  • Severe residual CNS disease/impairment [(other than hemiplegia alone) e.g. coma or intractable seizures]
  • Ventilatory failure
  • Major congenital anomalies that adversely affect survival, e.g. CNS malformations
  • Lansky score < 40% or Karnofsky score < 60%
  • HIV seropositivity
  • Diagnosis of Fanconi's anemia, Severe Combined Immunodeficiency (SCID)
  • Positive pregnancy test (For female patients in child bearing period)
  • Uncontrolled bacterial, viral, or fungal infections (currently taking medication yet clinical symptoms progress)
  • Disease specific exclusion criteria (as applicable per protocol).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00730314

Contacts
Contact: Hisham Abdel-Azim, MD 323-361-8556 habdelazim@chla.usc.edu

Locations
United States, California
Children Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90027
Sponsors and Collaborators
Children's Hospital Los Angeles
Investigators
Principal Investigator: Hisham Abdel-Azim, MD Childrens Hospital Los Angeles, University of Southern California
  More Information

Additional Information:
No publications provided

Responsible Party: Hisham Abdel-Azim, MD, Childrens Hospital Los Angeles, University of Southern California
ClinicalTrials.gov Identifier: NCT00730314     History of Changes
Other Study ID Numbers: CCI #07-00119, CHLA-#07-00119
Study First Received: August 6, 2008
Last Updated: June 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Hospital Los Angeles:
unrelated
BMT
HSCT
bone marrow transplantation
sickle cell disease
thalassemia
CGD
HLH
Blackfan-Diamond anemia
Hurler
leukodystrophy
LAD I
Genetic diseases
Red blood cell defects
Sickle cell disease
Thalassemia
Leukocyte defects and immune deficiencies
Hereditary Lymphohistiocytosis
chronic granulomatous disease
Wiskott-Aldrich syndrome
Chediak Higashi syndrome
CD40 ligand deficiency
Hyper IgM syndrome
leucocytes adhesion defect type 1
Osteopetrosis
congenital neutropenia
X-linked lymphoproliferative disease
Platelets defects
Congenital amegakaryocytic thrombocytopenia
Metabolic and storage disorders

Additional relevant MeSH terms:
Speech Disorders
Anemia, Sickle Cell
Aphasia, Primary Progressive
Chediak-Higashi Syndrome
Frontotemporal Dementia
Fucosidosis
Neutropenia
Niemann-Pick Disease, Type A
Niemann-Pick Disease, Type C
Niemann-Pick Diseases
Osteopetrosis
Pick Disease of the Brain
Syndrome
Thalassemia
Thrombocytopenia
Wiskott-Aldrich Syndrome
Agranulocytosis
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Aphasia
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Blood Platelet Disorders
Bone Diseases
Bone Diseases, Developmental
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Carbohydrate Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on November 24, 2014